Clinical trials: Hepatic Encephalopathy (HE)
Hepatic Encephalopathy, Cirrhosis, Liver
Prevention of Post-TIPS Hepatic Encephalopathy by Administration of Rifaximin and Lactulose
Rationale: Hepatic encephalopathy (HE) is a major and common complication in patients with liver cirrhosis. HE can be classified in the extensive range of neurocognitive deterioration as minimal HE (MHE), covert HE (grade I), or…
- Conditions
- Hepatic Encephalopathy, Cirrhosis, Liver, Portal Hypertension, Liver Diseases
- Trial name
- PEARL (NCT04073290)
- Testing
- Rifaximin 550 milligram Oral Tablet [XIFAXAN], Lactulose 667 milligram/milliliter Oral Solution
- Where
- 6 sites in Belgium, Netherlands
- Volunteers
- 238 people
- Sponsor
- Academisch Medisch Centrum - Universiteit van Amsterdam (AMC-UvA)
Hepatic Encephalopathy, Cirrhosis
Microbiota trAnSplant ThERaPy In hEpatiC Encephalopathy (MASTERPIECE)
The goal of this clinical trial is to find out whether changing the microbes in the bowels of Veterans with cirrhosis and hepatic encephalopathy (a condition that affects the brain as a result of liver problems) using capsules…
- Trial name
- MASTERPIECE (NCT07528690)
- Testing
- Microbiota transplant therapy (MTT) capsules
- Where
- 3 sites in United States
- Volunteers
- 162 people
- Sponsor
- VA Office of Research and Development
Cirrhosis, Hepatic Encephalopathy
VE303 for Treatment of Hepatic Encephalopathy (HE)
This research is studying the use of a new drug to learn about its safety and efficacy as a treatment for hepatic encephalopathy.
- Trial name
- NCT04899115
- Testing
- VE303, oral vancomycin
- Where
- United States
- Volunteers
- 19 people
- Sponsor
- Patricia Bloom
Cirrhosis, Hepatic Encephalopathy
A Study of Safety and Efficacy of HPN-100 in Subjects With Cirrhosis and Episodic Hepatic Encephalopathy
This is a phase 2 study of HPN-100 in subjects with hepatic encephalopathy (HE) consisting of an open label safety lead-in (Part A), followed by randomized, double-blind, placebo-controlled treatment (Part B).
- Trial name
- HALT-HE (NCT00999167)
- Testing
- HPN-100
- Where
- 28 sites in United States
- Volunteers
- 189 people
- Sponsor
- Amgen
Hepatic Encephalopathy, Cirrhosis
Metobolomics in the Characterisation of HE
Hepatic encephalopathy is (HE) defined by the neurological and/or neuropsychological symptoms caused by an acute or chronic liver disease and/or a portosystemic shunt.
- Trial name
- METABO-EH (NCT06245473)
- Testing
- blood sample
- Where
- 2 sites in France
- Volunteers
- 1 people
- Sponsor
- Assistance Publique - Hôpitaux de Paris
Hepatic Encephalopathy, Decompensated Cirrhosis
BCAA vs. Rifaximin in Patients With Cirrhosis for Secondary Prophylaxis of HE
Rationale Patients who recover from an episode of overt HE(OHE) are at risk of recurrent episodes of HE and persistent minimal hepatic encephalopathy, impacting their daily functioning and mental health.
- Conditions
- Hepatic Encephalopathy, Decompensated Cirrhosis, Minimal Hepatic Encephalopathy
- Trial name
- HERB (NCT06538077)
- Testing
- Oral Branched chain Amino acid, Rifaximin 550 MG, Lactulose
- Where
- India
- Volunteers
- 336 people
- Sponsor
- Post Graduate Institute of Medical Education and Research, Chandigarh
Liver Cirrhosis, Hepatic Encephalopathy
Cerebral Oxygen, Blood Flow and Ammonia Uptake in Patients With Cirrhosis and an Acute Episode of Hepatic Encephalopathy (HE)
We wish to study patients with liver cirrhosis during and 2 weeks after an acute episode of liver coma (hepatic encephalopathy).
- Trial name
- NCT01151475
- Where
- Denmark
- Volunteers
- 10 people
- Sponsor
- University of Aarhus
Cirrhosis, Refractory Ascites
Personalized Nutritional Intervention in Patients Undergoing TIPS Insertion for Refractory Ascites to Prevent Overt Hepatic Encephalopathy
This study will evaluate whether a nutritional intervention is better than another to reduce the incidence of overt hepatic encephalopathy in patients undergoing TIPS insertion for refractory ascites.
- Conditions
- Cirrhosis, Refractory Ascites, TIPS Insertion
- Trial name
- SUPPRESS-HE (NCT07634237)
- Testing
- High Energy and High Protein Diet 1, High Energy and High Protein Diet 2
- Where
- Canada
- Volunteers
- 50 people
- Sponsor
- McGill University Health Centre/Research Institute of the McGill University Health Centre
Mild Hepatic Encephalopathy
AST-120 Used to Treat Mild Hepatic Encephalopathy
The purpose of this study is to determine whether AST-120 is safe and effective in the treatment of mild hepatic encephalopathy.
- Trial name
- ASTUTE (NCT00867698)
- Testing
- AST-120
- Where
- 38 sites in United States
- Volunteers
- 148 people
- Sponsor
- Ocera Therapeutics
Hepatic Cirrhosis, Hepatic Encephalopathy (HE)
MNK6106 for Liver Disease (Hepatic Cirrhosis) That in the Past Has Affected the Brain (Hepatic Encephalopathy)
The main reason for this study is to see how the study drug interacts with the body. It will compare different doses of the study drug with a drug already in use.
- Trial name
- NCT03712280
- Testing
- MNK6106, Rifaximin
- Where
- 5 sites in United States, Puerto Rico
- Volunteers
- 50 people
- Sponsor
- Mallinckrodt